The Effect of Open-Label Semaglutide on Metabolic Dysfunction-Associated Steatotic Liver Disease in People With HIV

Ann Intern Med. 2024 Jun;177(6):835-838. doi: 10.7326/M23-3354. Epub 2024 Apr 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adult
  • Fatty Liver* / drug therapy
  • Female
  • Glucagon-Like Peptides* / adverse effects
  • Glucagon-Like Peptides* / therapeutic use
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Male
  • Middle Aged

Substances

  • semaglutide
  • Glucagon-Like Peptides
  • Hypoglycemic Agents